(Q24244876)

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

Complications associated with intraperitoneal chemotherapy catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

Intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

7 January 2021

Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

7 January 2021

Clinical pharmacology of intraperitoneal cisplatin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

7 January 2021

Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

7 January 2021

Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

7 January 2021

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

7 January 2021

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB2

7 January 2021